CFDB - Cystic Fibrosis DataBase

at least one term
all terms

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

primary studies  published RCT

Details
  • 2023
  • Uluer AZ

Embedded Specialist Palliative Care in Cystic Fibrosis: Results of a Randomized Feasibility Clinical Trial.

primary studies  published RCT

Details
  • 2023
  • Kavalieratos D

Efficacy of the Simeox(®) Airway Clearance Technology in the Homecare Treatment of Children with Clinically Stable Cystic Fibrosis: A Randomized Controlled Trial.

primary studies  published RCT

Details
  • 2023
  • Sands D

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.

primary studies  published RCT

Details
  • 2023
  • Stahl M

A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.

primary studies  published RCT

Details
  • 2022
  • Nash EF

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.

primary studies  published RCT

Details
  • 2023
  • Mayer-Hamblett N

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.

primary studies  published RCT

Details
  • 2023
  • Goralski JL

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

primary studies  published RCT

Details
  • 2023
  • Wainwright C

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.

primary studies  published RCT

Details
  • 2022
  • Rayment JH

Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection.

primary studies  published RCT

Details
  • 2022
  • Fischer R